argenx SE (ADR) share price logo

argenx SE (ADR)

NASDAQ: ARGX

Large Cap

$888.88

-29.34

(-3.20%)

as on

argenx SE (ADR) Stock Performance

as on July 28, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $888.48
    $919.16
    downward going graph

    0.05%

    Downside

    3.41%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $590.78
    $953.58
    downward going graph

    33.54%

    Downside

    7.28%

    Upside

    downward going graph

argenx SE (ADR) share price movements today

Previous Close
$918.22
Open
$915.84
Volume
234.5K
Day's Low - High
$888.48 - $919.16
52 Week Low - High
$590.78 - $953.58

argenx SE (ADR) Historical Returns

1 Month Return
+ 3.5 %
3 Month Return
+ 18.48 %
1 Year Return
+ 54.27 %
3 Year Return
+ 78.3 %
5 Year Return
+ 198.61 %

argenx SE (ADR) Stock Fundamentals & Key Indicators

Check argenx SE (ADR) market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$57.1B

EPS (TTM)

28.0045

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.95%

PE Ratio (TTM)

34.97

Industry PE ratio

-1.6812

PEG Ratio

1.5577

EBITDA

1.6B

Revenue (TTM)

5.3B

Profit Margin

32.27%

Return On Equity TTM

23.64%

argenx SE (ADR) Stock Valuation

Track how argenx SE (ADR) P/E has moved over time to understand its valuation trends.

argenx SE (ADR) in the last 5 years

  • Overview

  • Trends

Lowest (-126.07x)

September 30, 2023

Industry (-1.68x)

July 28, 2026

Today (34.97x)

July 28, 2026

Highest (135.07x)

March 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 34.97x

argenx SE (ADR) vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of argenx SE (ADR) with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
argenx SE (ADR) image
argenx SE (ADR)
BUY$57.1B198.61%34.9732.27%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$40.2B539.29%NA0.00%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$121.2B136.04%28.3335.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$68.8B11.87%16.0229.65%0.5499999999999999%

Stock Returns calculator for argenx SE (ADR) Stock including INR - Dollar returns

The argenx SE (ADR) stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

argenx SE (ADR) investment value today

Current value as on today

₹1,65,198

Returns

₹65,198

(+65.2%)

Returns from argenx SE (ADR) Stock

₹49,344 (+49.34%)

Dollar Impact

₹15,854 (+15.85%)

Analyst Recommendation on argenx SE (ADR) Stock

Based on 25 analysts

BUY

72.00%

Buy

24.00%

Hold

4.00%

Sell

Based on 25 analysts, 72% of analysts recommend a 'BUY' rating for argenx SE (ADR). Average target price of $1079.39

argenx SE (ADR) Share Price Target

Get share price movements and forecasts by analysts on argenx SE (ADR).

What analysts predicted

17.65%UPSIDE

Target Price

$1079.39

Current Price

$888.88

Analyzed by

25 Analysts

Target

$1079.39

argenx SE (ADR) target price $1079.39, a slight upside of 17.65% compared to current price of $888.88. According to 25 analysts rating.

Indian Investors' Interest in argenx SE (ADR) Stock

Search interest for argenx SE (ADR) Stock has decreased by -29% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-29% versus previous 30 day period

argenx SE (ADR) Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
401
970
636
1,346
790
947
1,126
3,205
1,298
1,515
Gross Profit
357
457
570
681
709
837
1,017
2,865
1,177
2,549
Operating Income
-93
-138
14
117
141
203
349
850
394
494
EBITDA
-73
-21
88
126
203
288
-
673
-
846
Interest Expense
0
0
0
0
1
1
0
1
1
2
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-74
-89
88
174
202
286
386
991
426
958
Income Tax Expense
-12
-56
-3
33
32
41
-
-54
-
119
Net Income
-61
-35
101
865
169
245
344
1,046
366
838
Net Profit Margin
-15.36%
-3.61%
15.95%
64.29%
21.43%
25.88%
30.55%
32.65%
28.20%
55.37%

argenx SE (ADR) Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
16
51
27
87
50
562
434
1,337
2,190
4,153
Gross Profit
16
51
27
87
50
562
403
1,209
1,962
3,702
Operating Income
-22
-27
-93
-198
-477
-348
-720
-425
-21
1,054
EBITDA
-22
-32
-93
-173
-601
-392
-622
-192
105
1,310
Interest Expense
-
5
35
0
0
1
2
0
2
4
Depreciation
-
0
0
2
3
5
104
111
17
28
Income Before Tax
-22
-32
-75
-175
-605
-399
-729
-304
85
1,278
Income Tax Expense
0
0
0
5
3
8
-19
-9
-747
-13
Net Income
-23
-39
-86
-201
-740
-460
-750
-321
833
1,292
Net Profit Margin
-145.27%
-77.10%
-310.22%
-230.95%
-1475.29%
-81.97%
-172.76%
-24.06%
38.03%
31.11%

argenx SE (ADR) Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-32
84
865
149
418
344
635
366
472
Operating Cash Flow
-124
-
41
-
437
-
407
-
-
Investing Cash Flow
-513
-
-203
-
-10
-
829
-
-
Financing Cash Flow
40
-
239
-
74
-
158
-
-
Change in Cash
-610
-
61
-
586
-
1,405
-
-

argenx SE (ADR) Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-27
-93
-198
-477
-348
-720
-425
833
1,053
Operating Cash Flow
-43
-61
151
-398
-606
-862
-420
-82
850
Investing Cash Flow
-194
-123
-833
344
-347
-461
308
-717
823
Financing Cash Flow
366
279
733
833
1,119
843
1,336
279
233
Change in Cash
121
103
50
844
117
-533
1,248
-548
1,991

Mutual Funds that own argenx SE (ADR) Stock

Check out the Mutual Funds with significant holdings in argenx SE (ADR).

Global Institutional Holdings in argenx SE (ADR)

Funds
Holdings
William Blair Investment Management, LLC
0.43%
T. Rowe Price Associates, Inc.
5.4%
Capital World Investors
3.61%
Artisan Partners Limited Partnership
2.35%
Wellington Management Company LLP
1.63%
See all

argenx SE (ADR) News & Key Events

  • img

    Today's Timeline - 27 July

    Mon, 04:16 PM

    -

    Argenx announces acquisition of Forte Biosciences for $2.2 billion, enhancing its immunology pipeline with FB102.

Insights on argenx SE (ADR)

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    argenx SE American Depositary Shares have shown strong profit growth over the last two quarters. The net profit increased from $365.99 million to $838.82 million, which represents an average growth of 56.4% per quarter.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    argenx SE American Depositary Shares has shown positive revenue growth over the last two quarters. Revenue increased from $1.29 billion to $1.51 billion, representing an average increase of 14.3% per quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ARGX stock has moved up by 5.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 407.9% return, outperforming this stock by 353.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 636.0% return, outperforming this stock by 557.7%

About argenx SE (ADR)

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Organisationargenx SE (ADR)
HeadquartersLaarderhoogtweg 25, Amsterdam, Netherlands, 1101 EB
IndustryBiotechnology
CEOMs. Karen Massey
E-voting on sharesClick here to vote

Key Management of argenx SE (ADR)

Name

Title

Ms. Karen Massey

CEO & Executive Director

Dr. Peter Ulrichts

Chief Scientific Officer

Ms. Malini Moorthy

General Counsel & Corporate Secretary

Mr. Arjen Lemmen M.Sc.

Vice President of Corporate Development & Strategy

Ms. Andria Wilk

Global Head of Quality

Mr. Timothy Van Hauwermeiren EMBA, M.Sc.

Co-Founder & Non-Independent Non-Executive Chairman of the Board

Mr. Karl Gubitz

Chief Financial Officer

Dr. Luc Truyen

Chief Medical Officer

Prof. Hans de Haard Ir, Ph.D.

Co-Founder & Member of Board Advisors

Mr. Filip Borgions

Chief Technology Innovation Officer

FAQs

What is argenx SE (ADR) share price today?

argenx SE (ADR) share price today is $888.88 as on at the close of the market. argenx SE (ADR) share today touched a day high of $919.16 and a low of $888.48.

What is the 52 week high and 52 week low for argenx SE (ADR) share?

argenx SE (ADR) share touched a 52 week high of $953.58 on and a 52 week low of $590.78 on . argenx SE (ADR) stock price today i.e. is closed at $888.88,which is 6.78% down from its 52 week high and 50.46% up from its 52 week low.

What is argenx SE (ADR)'s market capitalisation today?

argenx SE (ADR) market capitalisation is $0.06T as on .

How to invest in argenx SE (ADR) Stock (ARGX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for argenx SE (ADR) on INDmoney app. Click on Buy button. You can invest as low as $1.5 in argenx SE (ADR) Shares that will get you 0.0017 shares as per argenx SE (ADR) share price of $888.88 per share as on July 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy argenx SE (ADR) Stock (ARGX) from India?

Indian investors can start investing in argenx SE (ADR) (ARGX) shares with as little as ₹95.9 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹959.00 in argenx SE (ADR) stock (as per the Rupee-Dollar exchange rate as on ). Based on argenx SE (ADR) share’s latest price of $888.88 as on July 28, 2026 at 1:29 am IST, you will get 0.0113 shares of argenx SE (ADR). Learn more about fractional shares .

What are the returns that argenx SE (ADR) has given to Indian investors in the last 5 years?

argenx SE (ADR) stock has given 198.61% share price returns and 29.61% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?